TABLE 2.
Baseline characteristics of the study population (N = 189).
| Variables | Mean+SD/N (%) |
| Age (year) | 65.44 ± 9.26 |
| Age | |
| – < 60 years | 51(26.98%) |
| – ≥ 60 years | 138(73.02%) |
| Male (N, %) | 163(86.24%) |
| BMI (kg/m2) | 28.29 ± 3.87 |
| BMI | |
| – Normal weight (18.5–25, kg/m2) | 38(20.11%) |
| – Overweight (25–30, kg/m2) | 91(48.15%) |
| – Obese (≥ 30, kg/m2) | 60(31.75%) |
| Hypertension (N, %) | 113(59.79%) |
| Dyslipidemia (N, %) | 77(40.74%) |
| Diabetes mellitus (N, %) | 62(32.80%) |
| Left ventricular dysfunction (N, %) | 42(22.22%) |
| Left atrial dilatation > 45 mm (N, %) | 21(11.11%) |
| ACEI/ARB/AT2 antagonist (N, %) | 131(69.31%) |
| Statin (N, %) | 170(89.95%) |
| Antiarrhythmic drugs | |
| – Class I (N, %) | 1(0.53%) |
| – Class II (N, %) | 150(79.37%) |
| – Class IIII (N, %) | 3(1.59%) |
| – Class IV (N, %) | 11(5.82%) |
| – Digoxin (N, %) | 2(1.07%) |
Values are presented as N (%), mean ± standard deviation.ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AT2, angiotensin type 2 receptor; BMI, body mass index.